

BIOCON LIMITED (CONSOLIDATED)	
BALANCE SHEET	(Rs. Crores)

BALANCE SHEET	ALANCE SHEET (Rs. Crores			
	June 30, 2015	March 31, 2015		
EQUITY AND LIABILITIES				
Shareholder's Funds				
(a) Share capital	100	100		
(b)Reserves and surplus	3,298	3,171		
	3,398	3,271		
Minority interest	184	172		
•				
Non-current liabilities				
(a) Long-term borrowings	761	770		
(b)Deferred tax liability (net)	37	42		
(c)Other long-term liabilities	557	552		
(d) Long-term provisions	17	15		
	1,372	1,379		
	,-	,= -		
Current liabilities				
(a)Short-term borrowings	259	261		
(b)Trade payables	463	429		
(c)Other current liabilities	687	706		
(d)Short-term provisions	92	157		
(a) a real control provides and	1,501	1,553		
TOTAL	6,455	6,375		
	,	·		
ASSETS				
Non-current assets				
(a) Fixed assets	3,424	3,280		
(b) Goodwill	26	26		
(c) Long term loans and advances	383	369		
(d) Other non-current assets	135	137		
	3,968	3,812		
		,		
Current assets				
(a) Current Investments	231	230		
(b) Inventories	462	453		
(c)Trade receivables	763	771		
(d)Cash and cash equivalents	816	938		
(e)Short term loans and advances	112	81		
(f)Other current assets	103	90		
(.,	2,487	2,563		
	2,407	2,303		
TOTAL	6,455	6,375		
	<del>0,1</del> 33	0,373		

## BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT

(Rs. Crores)

PROFIT & LOSS STATEMENT (F			(Rs. Crores)
Particulars	Q1 FY 16	Q1 FY 15	Variance
INCOME			
Total sales	825	719	15%
Other income	32	23	37%
Total Revenue	857	742	15%
<u>EXPENDITURE</u>			
Material & Power costs	363	334	9%
Staff costs	141	116	22%
Research & Development **	50	31	60%
Other expenses	67	70	-4%
Manufacturing, staff & other expenses	621	551	
EBITDA	236	191	24%
Interest & Finance charges	5	1	
Depreciation & Amortisation	58	52	11%
PBT	173	138	24%
Taxes	37	31	
NET PROFIT BEFORE MINORITY INTEREST	136	107	27%
Minority interest	10	4	
NET PROFIT FOR THE PERIOD	126	103	23%
EPS Rs.	6.3	5.2	
Note: The figures are rounded off to the nearest crores, percent	tages are based on absolute numbe	ers	
* Total sales includes:			
Licensing Income	19	19	
** Gross Research & Development expenses	93	63	

## BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT

(Rs. Crores)

PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 16	Q4 FY 15	Variance
INCOME			
Total Sales	825	830	-1%
Other income	32	24	32%
TOTAL REVENUE	857	854	0%
<u>EXPENDITURE</u>			
Material & Power costs	363	376	-4%
Staff costs	141	126	12%
Research & Development **	50	56	-11%
Other expenses	67	94	-29%
Manufacturing, staff & other expenses	621	652	
EBITDA	236	202	17%
Interest & Finance charges	5	-	
Depreciation & Amortisation	58	59	-1%
PBT BEFORE EXCEPTIONAL ITEM	173	143	21%
Exceptional item, net		105	
PBT	173	248	-30%
Current taxes	37	22	
Taxes on exceptional items	-	10	
NET PROFIT BEFORE MINORITY INTEREST	136	216	-37%
Minority interest	10	15	-32%
NET PROFIT FOR THE PERIOD	126	201	-37%
EPS Rs.	6.3	10.0	
Note: The figures are rounded off to the nearest crores, percent	ages are based on absolute numbe	ers	
* Total sales includes:			
Licensing Income	19	5	
** Gross Research & Development expenses	93	100	